This study is to investigate breath analysis (breath metabolomics) combined with established bioinformatic tools as a platform for companion diagnostics.
Age 0 ≤ 22 years at study entry and signed informed consent
Acute disease: - Acute signs for a respiratory disease, indicated by e.g. increased work of breathing (e.g. dyspnea, increased respiratory rate), cough or wheezing.
Chronic disease: - Suspected or confirmed chronic airway disease (e.g. asthma).
Acute disease: - Acute presentation or report within 24 hours of any signs of neurological deficit (motor function, sensoneural, or verbal).
Physical or intellectual impairment precluding protocol adherence.
Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and/or pharmacological treatment and is associated with an inflammatory response, relevant congenital defects
Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), known inflammatory diseases (e.g. autoimmune disease) that require medical and/or pharmacological treatment and is associated with an inflammatory response, relevant congenital defects.
Known malignancy, active smoker (passive smoke exposure is not an exclusion criterium), relevant congenital defects.
12
Treatment groupsSee each treatment group below.
University Children's Hospital Basel
Lead sponsor
Swiss National Science Foundation
Collaborator
Fondation Botnar (Switzerland)
Collaborator